SCHEMBL14825429

SCHEMBL14825429

O=C(O)c1cccnc1CN1CCC(OC(c2ccccc2)c2ccc(F)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 5/20 0.52
▸ SLC6A2 P23975 2/20 0.43
▸ DRD3 P35462 2/20 0.43
▸ OPRM1 P35372 2/20 0.43
▸ DRD2 P14416 1/20 0.43
▸ DRD4 P21917 1/20 0.43
▸ FAAH O00519 1/20 0.42
▸ SLC6A3 Q01959 3/20 0.41
▸ GRM5 P41594 1/20 0.41
▸ GRM7 Q14831 1/20 0.41
▸ GRM3 Q14832 1/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ ADRA2A P08913 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ DRD1 P21728 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825217 0.94 BCHE (0.48) BCHESLC6A2DRD3OPRM1DRD2
SCHEMBL14825428 0.89 BCHE (0.51) BCHESLC6A2DRD3OPRM1DRD2
SCHEMBL14825215 0.82 BCHE (0.48) BCHESLC6A2DRD3OPRM1DRD2
SCHEMBL4022557 0.81 BCHE (0.57) BCHESLC6A2DRD3OPRM1DRD2
SCHEMBL14813910 0.80 BCHE (0.55) BCHESLC6A2DRD3OPRM1DRD2
SCHEMBL12064937 0.80 BCHE (0.51) BCHESLC6A2DRD3DRD2DRD4
SCHEMBL14825821 0.78 BCHE (0.52) BCHESLC6A2DRD3DRD2DRD4
SCHEMBL14825457 0.78 MEN1 (0.56) SLC6A2DRD3OPRM1DRD2SLC6A3
SCHEMBL9353208 0.78 BCHE (0.62) BCHESLC6A2DRD3OPRM1DRD2
SCHEMBL14813841 0.77 BCHE (0.48) BCHESLC6A2DRD3OPRM1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 — — EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 BCHE 2942/4885SLC6A2 2688/4885DRD3 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback